doi: 10.1128/AAC.46.4.1105-1107.2002.
Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis
Affiliations
- PMID: 11897598
- PMCID: PMC127106
- DOI: 10.1128/AAC.46.4.1105-1107.2002
Item in Clipboard
Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis
Antimicrob Agents Chemother.
2002 Apr.
Abstract
Azithromycin and clarithromycin were paired with other antibiotics to test synergistic activity against 300 multidrug-resistant pathogens isolated from cystic fibrosis (CF) patients. Clarithromycin-tobramycin was most active against Pseudomonas aeruginosa and inhibited 58% of strains. Azithromycin-trimethoprim-sulfamethoxazole, azithromycin-ceftazidime, and azithromycin-doxycycline or azithromycin-trimethoprim-sulfamethoxazole inhibited 40, 20, and 22% of Stenotrophomonas maltophilia, Burkholderia cepacia complex, and Achromobacter (Alcaligenes) xylosoxidans strains, respectively.
Similar articles
-
Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.Antimicrob Agents Chemother. 2001 Oct;45(10):2838-44. doi: 10.1128/AAC.45.10.2838-2844.2001. Antimicrob Agents Chemother. 2001. PMID: 11557478 Free PMC article.
-
In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis.J Med Microbiol. 2018 Sep;67(9):1217-1220. doi: 10.1099/jmm.0.000801. Epub 2018 Jul 17. J Med Microbiol. 2018. PMID: 30016231
-
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.J Antimicrob Chemother. 2001 Oct;48(4):549-52. doi: 10.1093/jac/48.4.549. J Antimicrob Chemother. 2001. PMID: 11581236
-
Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.Am J Respir Med. 2003;2(4):321-32. doi: 10.1007/BF03256660. Am J Respir Med. 2003. PMID: 14719998 Review.
-
Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.Curr Opin Pulm Med. 2000 Nov;6(6):545-50. doi: 10.1097/00063198-200011000-00015. Curr Opin Pulm Med. 2000. PMID: 11100967 Review.
Cited by
-
A Case of Septic Shock caused by Achromobacter xylosoxidans in an Immunocompetent Female Patient after Extracorporeal Shock Wave Lithotripsy for a Ureteral Stone.Infect Chemother. 2016 Mar;48(1):47-50. doi: 10.3947/ic.2016.48.1.47. Epub 2016 Mar 31. Infect Chemother. 2016. PMID: 27104016 Free PMC article.
-
Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.Antimicrob Agents Chemother. 2017 Mar 24;61(4):e00096-16. doi: 10.1128/AAC.00096-16. Print 2017 Apr. Antimicrob Agents Chemother. 2017. PMID: 28096154 Free PMC article.
-
Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa.Antimicrob Agents Chemother. 2012 Mar;56(3):1529-38. doi: 10.1128/AAC.05958-11. Epub 2012 Jan 9. Antimicrob Agents Chemother. 2012. PMID: 22232284 Free PMC article.
-
Cloning, overexpression, and characterization of a novel thermostable penicillin G acylase from Achromobacter xylosoxidans: probing the molecular basis for its high thermostability.Appl Environ Microbiol. 2004 May;70(5):2764-70. doi: 10.1128/AEM.70.5.2764-2770.2004. Appl Environ Microbiol. 2004. PMID: 15128530 Free PMC article.
-
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.Mayo Clin Proc. 2011 Mar;86(3):250-9. doi: 10.4065/mcp.2010.0674. Mayo Clin Proc. 2011. PMID: 21364117 Free PMC article. Review.
References
-
- Burns, J. L., J. Emerson, J. R. Stapp, D. L. Yim, J. Krzewinski, L. Louden, B. W. Ramsey, and C. R. Clausen. 1998. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:158-163. - PubMed
-
- Dupont, M., and J. Lapointe. 1995. Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum onto Pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampin. J. Antimicrob. Chemother. 36:231-236. - PubMed
-
- FitzSimmons, S. C. 1993. The changing epidemiology of cystic fibrosis. J. Pediatr. 122:1-9. - PubMed
-
- Henry, R. L., C. M. Mellis, and L. Petrovic. 1992. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr. Pulmonol. 12:158-161. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
